Macroautophagy: a mechanism for mediating cell death or for promoting cell survival?  by Lieberthal, Wilfred
Kidney International (2008) 74          555
commentar y
6. Walter DH, Rittig K, Bahlmann FH et al. Statin 
therapy accelerates reendothelialization: a novel 
effect involving mobilization and incorporation of 
bone marrow-derived endothelial progenitor cells. 
Circulation 2002; 105: 3017–3024.
7. Jerwood S, Cohen J. Unexpected antimicrobial 
effect of statins. J Antimicrob Chemother 2008; 61: 
362–364.
8. Haslinger B, Goedde MF, Toet KH, Kooistra T. 
Simvastatin increases fibrinolytic activity in 
human peritoneal mesothelial cells independent 
of cholesterol lowering. Kidney Int 2002; 62: 
1611–1619.
9. Haslinger B, Kleemann R, Toet KH, Kooistra T. 
Simvastatin suppresses tissue factor expression 
and increases fibrinolytic activity in tumor 
necrosis factor-alpha-activated human peritoneal 
mesothelial cells. Kidney Int 2003; 63: 2065–2074.
10. Chatterjee PK. Novel pharmacological approaches 
to the treatment of renal ischemia-reperfusion 
injury: a comprehensive review. Naunyn 
Schmiedebergs Arch Pharmacol 2007; 376: 1–43.
see original article on page 631
Macroautophagy: a mechanism 
for mediating cell death or for 
promoting cell survival?
Wilfred Lieberthal1
Macroautophagy is a ubiquitous mechanism for the bulk removal 
of macromolecules and cell organelles from the cell. Periyasamy-
Thandavan and colleagues report that cisplatin activates autophagy 
in renal tubular cells and that autophagy plays a role in decreasing 
apoptosis of tubular cells induced by cisplatin. This finding provides 
novel evidence that autophagy may play a role in ameliorating the 
effects of acute injury on the kidney.
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There are three types of autophagy. Micro-
autophagy is a process that has been well 
characterized only in yeast; during this 
process cytosolic components are seques-
tered by lysosomes at the lysosomal mem-
brane by septation and/or invagination. 
Chaperone-mediated autophagy is the 
direct translocation across the lyso-
somal membrane of cytosolic proteins 
that have been ‘tagged’ with a specific 
peptide sequence. This Commentary 
will focus entirely on macroautophagy 
(hereafter referred to as autophagy), 
which is a ubiquitous, genetically pro-
grammed and evolutionarily conserved 
process in which long-lived cytoplasmic 
components, including macromolecular 
aggregates and cellular organelles (such 
as mitochondria, peroxisomes, and endo-
plasmic reticulum), are sequestered into 
vesicles for bulk degradation by a lyso-
somal degradative pathway.1–3
The process of autophagy begins with 
the formation of crescent-shaped ‘ini-
tiation’ membranes that envelop and 
sequester cytosolic components before 
forming double-membraned vesicles called 
autophagosomes (Figure 1). The origin of 
initiation membranes remains uncertain. 
Autophagosomes fuse with lysosomes 
to form autolysosomes, which degrade 
the sequestered contents into their basic 
components (amino acids, fatty acids, 
and so on). These molecules are returned 
to the cytosol for recycling (Figure 1).1–3 
Although the proteasome provides another 
mechanism for mass degradation of pro-
teins, this process requires proteins to be 
tagged by ubiquitination and to be unfolded 
so they can enter the degradative ubiquiti-
nation channel. In contrast, autophagy has 
the ability to degrade all forms of peptide 
and lipid macromolecules as well as entire 
cellular organelles.
Autophagy is a genetically programmed 
process. Autophagy-related genes (ATGs) 
were first isolated in yeast. Subsequently, 
a number of mammalian orthologues of 
yeast ATGs have been identified. These 
genes encode the proteins necessary for 
the complex series of events that consti-
tute the autophagic cycle (Figure 1).1–3 The 
signaling mechanisms responsible for the 
regulation of autophagy remain uncertain. 
However, it is clear that autophagy is acti-
vated by the target of rapamycin complex 1 
(TORC1), as factors that activate TORC1 
(insulin and growth factors) stimulate 
autophagy, and rapamycin-induced inhi-
bition of TORC1 reduces autophagy.2,4,5
The biologic processes controlled by 
autophagy in mammals have not yet been 
clearly elucidated. Paradoxically, current 
evidence appears to suggest that autophagy 
can cause cell death in some situations 
while acting as a prosurvival mechanism 
in others.5 ‘Autophagic cell death’ is pre-
sumed to result from an excessive level of 
cellular autophagy and is a form of pro-
grammed cell death (PCD type II) that is 
morphologically distinct from apoptosis 
(PCD type I).3 Apoptosis is characterized 
by cell shrinkage, DNA fragmentation, and 
the rapid phagocytic removal and degra-
dation of apoptotic cell fragments. In con-
trast, autophagic cell death is associated 
morphologically with the accumulation 
of autophagic vesicles (autophagosomes). 
A fundamental feature that distinguishes 
apoptosis from autophagic cell death is the 
source of the lysosomal enzymes used for 
degrading the dying cells. Apoptotic cells 
are degraded by the lysosomes of phago-
cytic cells, whereas in autophagy the 
endogenous lysosomal machinery of the 
dying cell serves this purpose.5
What data support the view that 
autophagy can cause cell death? There are 
morphologic studies that have demonstrated 
the accumulation of increased numbers of 
dying cells containing many autophago-
somes in some disease states, such as 
degenerative diseases of brain and muscle.3,4 
However, these findings are only correlative 
in nature and cannot be considered direct 
556   Kidney International (2008) 74 
commentar y
proof of autophagic cell death. Studies using 
pharmacologic agents have demonstrated 
that inhibition of autophagy can prevent cell 
death.3,6,7 However, in many of these stud-
ies, autophagy appears to have triggered 
apoptosis, rather than acting as the direct 
cause of cell death. Other in vitro studies, 
in which the expression of genes essential 
for autophagy were ‘silenced’ with RNA 
interference (RNAi), have provided the 
most convincing evidence to date that the 
autophagy is capable of killing cells, at least 
under some circumstances. In cells treated 
with caspase inhibitors8 and in murine 
embryonic fibroblasts lacking the proapop-
totic protein Bax or Bak,9 inhibition of the 
expression of autophagy genes with RNA-
mediated interference induced autophagic 
cell death. However, in both reports, the 
apoptotic pathway was defective in the 
cells studied. Although these studies clearly 
demonstrate that autophagy can induce cell 
death by pathways independent of apopto-
sis, they still leave unresolved the question 
of whether autophagy can ever cause death 
in cells in which the apoptotic machinery is 
intact. Thus, although many different lines 
of evidence suggest that autophagic cell 
death can occur, the importance of this form 
of cell death in physiologic or pathologic 
states remains to be determined by further 
scientific scrutiny.3,5
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figure 1 | The autophagic cycle. Autophagy is a lysosomal pathway that is responsible for the bulk 
degradation of macromolecules and cytoplasmic organelles. Autophagy is initiated by the formation of 
small, crescent-shaped membrane structures that elongate and enlarge into double-membraned vesicles 
called autophagosomes. Autophagosomes sequester macromolecules and organelles within the cytosol. 
Then the outer membrane of the autophagosome fuses with a lysosome to form an autolysosome. The 
contents of the autolysosome are degraded by acidic lysosomal hydrolases, and the resultant products of 
this process (amino acids, lipids, and other molecules) are returned to the cytosol for reuse.
Although the role of autophagic cell 
death seems as yet uncertain, there is more 
substantial evidence that autophagy can 
promote cell survival.10 In fact, autophagy 
represents an ancient and evolutionarily 
conserved mechanism that is essential for 
supporting cell survival in the absence of 
nutrients or growth factors.10 The re-addi-
tion of nutrients or growth factors after 
periods of deficiency generally leads to con-
tinued cell viability.10 However, if growth 
factor or nutrient depletion continues for 
too long, cells will ultimately die by apopto-
sis. Thus, autophagy appears to represent a 
highly effective, if self-limited, mechanism 
for prolonging cell survival in the absence 
of nutrients and growth factors.10
More recent data suggest that autophagy 
can protect cells against acute injury induced 
by hypoxia and oxidative injury.1–3,11,12 
Periyasamy-Thandavan et al.13 (this issue) 
provide highly novel evidence that cispla-
tin activates autophagy within renal tubular 
cells, and that inhibition of autophagy pro-
motes apoptosis of cultured renal tubular 
cells treated with cisplatin. This study is the 
first to demonstrate a role for autophagy in 
ameliorating the functional and structural 
effects of acute renal injury induced by cis-
platin.13 The extent to which autophagy 
can ameliorate acute kidney injury caused 
by other types of renal insults (such as 
ischemia) remains to be determined.
The mechanisms responsible for the 
prosurvival effect of autophagy are uncer-
tain. It seems likely that some benefits 
of autophagy are metabolic in nature.10 
Autophagy degrades unnecessary mac-
romolecules and organelles into nutrients 
that can be reused for generating energy 
and for rebuilding essential cell structures. 
This mechanism most likely explains the 
survival effect of autophagy when it is 
activated by periods of bioenergetic stress 
imposed by decreased extracellular supply 
of nutrients or cell injury. The amino acids 
generated by autophagy can be processed 
to support the tricarboxylic acid (TCA) 
cycle, which carries out two important 
prosurvival functions. The TCA cycle is an 
important source of FADH2 and NADH 
(which are necessary for ATP generation 
by the electron transport chain) and can 
also convert intermediates in the cycle into 
various metabolites, including cytosolic 
acetyl-coenzyme A (acetyl-CoA), ster-
ols, and nucleotides. Loss of TCA cycle 
activity would compromise the ability of 
the cell to generate these substances. The 
importance of constitutive TCA activity 
in autophagic cells is supported by studies 
showing that providing pyruvate, a TCA 
substrate, during nutrient deprivation sup-
presses autophagy while maintaining cell 
viability. In addition, the turnover of lipids 
during autophagy might also be important 
in maintaining cell viability. Acetyl-CoA, 
an end product of β-oxidation and gly-
colysis, combines with oxaloacetate in the 
entry step of the TCA cycle. A deficiency 
of acetyl-CoA would result in decreased 
TCA activity, even in the presence of suf-
ficient oxaloacetate. In cells confronting a 
deficiency of nutrients, β-oxidation might 
play an increasingly important part in sup-
plying acetyl-CoA.
In addition to its role in optimizing meta-
bolic conditions in stressed cells, autophagy 
may also function as a ‘waste disposal’ 
system, clearing fully formed cytosolic 
organelles that accumulate from the cyto-
plasm and that are injurious to the cell. 
It is not yet known whether the disposal 
system of autophagy occurs randomly or 
whether it involves the selective targeting 
of particular organelles. However, it is pos-
sible that autophagy preferentially removes 
aging or oxidatively damaged organelles 
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and protein aggregates that have the poten-
tial to cause or exacerbate cell injury. This 
could be particularly important for dam-
aged mitochondria, which have a decreased 
ability to produce ATP and an increased 
potential for producing toxic reactive oxy-
gen species. Another important organelle 
that may be targeted for turnover through 
autophagy is the peroxisome. Peroxisomes 
are organelles that function in lipid metab-
olism and breakdown of hydrogen peroxide 
and are ‘marked’ for turnover when they 
are in excess or damaged. The role played 
by autophagy in promoting cell survival 
by preventing the accumulation of aged or 
damaged cytosolic organelles and macro-
molecules still needs to be determined by 
additional research.
In summary, autophagy has entered the 
research spotlight during the past few years 
because of the discovery of mammalian 
orthologues of yeast autophagy genes and 
the elucidation of the mechanisms involved 
in the autophagic cycle (Figure 1). These 
studies have revealed the highly conserved 
nature of autophagy and have implicated 
autophagy pathogenesis of a wide array of 
disease states. The study by Periyasamy-
Thandavan et al.13 highlights the potential 
role of autophagy as a survival mechanism 
following cytotoxic injury to the kidney and 
is also relevant to the potential protective 
role of autophagy in acute injury to other 
organs, such as brain, heart, and liver.6,11
As our understanding of the mecha-
nisms involved in autophagy continues to 
evolve, it is likely that specific pharmaco-
logic agents will become available that can 
enhance or inhibit autophagic activity.14 
These agents could prove useful for the 
treatment of diseases in which autophagy 
plays an important role.14 However, a great 
deal of additional research is necessary in 
order to define the role of autophagy in 
the pathogenesis of different disease states 
before we are able to determine the thera-
peutic utility of pharmacologic agents that 
modulate the autophagic cycle.
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Once-yearly intravenous 
zoledronate does not impair  
renal function in  
postmenopausal women
Marie-Hélène Lafage-Proust1
Zoledronate, a potent third-generation amino-bisphosphonate 
previously used for the treatment of bone metastasis, was recently 
shown to significantly reduce the risk of vertebral and hip fractures in 
osteoporotic postmenopausal women when infused at a dose of  
5 mg per year for 3 years. The renal follow-up of this pivotal study that 
included more than 5,000 patients (estimated creatinine clearance  
>30 ml per min) is reported by Boonen et al. and shows the long-term 
renal safety of zoledronate in this osteoporotic population.
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Bisphosphonates, potent inhibitors of 
osteoclastic resorption, are bone-seeking 
drugs with very high affinity for mineral-
ized collagen matrix. Therefore, they are 
cleared rapidly from the circulation, with 
about half the administered dose taken 
up by the skeleton while the other half is 
excreted, unmetabolized, by the kidneys.1 
After being embedded in bone at the 
remodeling sites,2 they are slowly released 
from bone into the circulation,3 when a 
remodeling cycle is again initiated at the 
bone surface. Therefore, because bisphos-
phonates remain in bone for years when 
administered daily, the idea of exploiting 
the considerable skeletal persistence of 
these drugs was raised, and bisphospho-
nates were then given weekly, and after 
that monthly, and are now proposed to 
